J. L. Bainbridge & Co., Inc. Biogen Inc. Transaction History
J. L. Bainbridge & Co., Inc.
- $937 Million
- Q1 2025
A detailed history of J. L. Bainbridge & Co., Inc. transactions in Biogen Inc. stock. As of the latest transaction made, J. L. Bainbridge & Co., Inc. holds 124,522 shares of BIIB stock, worth $15.9 Million. This represents 1.82% of its overall portfolio holdings.
Number of Shares
124,522
Previous 97,983
27.09%
Holding current value
$15.9 Million
Previous $15 Million
13.72%
% of portfolio
1.82%
Previous 1.43%
Shares
5 transactions
Others Institutions Holding BIIB
# of Institutions
1,025Shares Held
127MCall Options Held
2.29MPut Options Held
4.26M-
Vanguard Group Inc Valley Forge, PA17MShares$2.17 Billion0.04% of portfolio
-
Primecap Management CO Pasadena, CA15.9MShares$2.03 Billion1.84% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$1.85 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.4MShares$943 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA4.67MShares$596 Million0.13% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $18.4B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...